Keros Therapeutics Inc. (KROS)
Keros Therapeutics Statistics
Share Statistics
Keros Therapeutics has 40.56M shares outstanding. The number of shares has increased by 12.41% in one year.
Shares Outstanding | 40.56M |
Shares Change (YoY) | 12.41% |
Shares Change (QoQ) | 0.13% |
Owned by Institutions (%) | 99.99% |
Shares Floating | 32.88M |
Failed to Deliver (FTD) Shares | 29 |
FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 4.02M, so 9.92% of the outstanding shares have been sold short.
Short Interest | 4.02M |
Short % of Shares Out | 9.92% |
Short % of Float | 12.23% |
Short Ratio (days to cover) | 2.14 |
Valuation Ratios
The PE ratio is -3.16 and the forward PE ratio is -3.11. Keros Therapeutics's PEG ratio is 0.82.
PE Ratio | -3.16 |
Forward PE | -3.11 |
PS Ratio | 166.94 |
Forward PS | 3.2 |
PB Ratio | 1.04 |
P/FCF Ratio | -3.64 |
PEG Ratio | 0.82 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Keros Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.45, with a Debt / Equity ratio of 0.03.
Current Ratio | 21.45 |
Quick Ratio | 21.45 |
Debt / Equity | 0.03 |
Debt / EBITDA | -0.1 |
Debt / FCF | -0.12 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $21.01K |
Profits Per Employee | $-1.11M |
Employee Count | 169 |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | 300K |
Effective Tax Rate | -0.16% |
Stock Price Statistics
The stock price has increased by -84.31% in the last 52 weeks. The beta is 1.4, so Keros Therapeutics's price volatility has been higher than the market average.
Beta | 1.4 |
52-Week Price Change | -84.31% |
50-Day Moving Average | 11.1 |
200-Day Moving Average | 38.31 |
Relative Strength Index (RSI) | 35.1 |
Average Volume (20 Days) | 1.33M |
Income Statement
In the last 12 months, Keros Therapeutics had revenue of 3.55M and earned -187.35M in profits. Earnings per share was -5.
Revenue | 3.55M |
Gross Profit | 3.55M |
Operating Income | -210.83M |
Net Income | -187.35M |
EBITDA | -185.82M |
EBIT | -187.05M |
Earnings Per Share (EPS) | -5 |
Balance Sheet
The company has 559.93M in cash and 18.86M in debt, giving a net cash position of 541.07M.
Cash & Cash Equivalents | 559.93M |
Total Debt | 18.86M |
Net Cash | 541.07M |
Retained Earnings | -568.78M |
Total Assets | 615.89M |
Working Capital | 561.44M |
Cash Flow
In the last 12 months, operating cash flow was -160.87M and capital expenditures -1.93M, giving a free cash flow of -162.8M.
Operating Cash Flow | -160.87M |
Capital Expenditures | -1.93M |
Free Cash Flow | -162.8M |
FCF Per Share | -4.35 |
Margins
Gross margin is 100%, with operating and profit margins of -5938.96% and -5277.55%.
Gross Margin | 100% |
Operating Margin | -5938.96% |
Pretax Margin | -5269.1% |
Profit Margin | -5277.55% |
EBITDA Margin | -5234.48% |
EBIT Margin | -5938.96% |
FCF Margin | -4585.92% |
Dividends & Yields
KROS does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for KROS is $26, which is 159% higher than the current price. The consensus rating is "Hold".
Price Target | $26 |
Price Target Difference | 159% |
Analyst Consensus | Hold |
Analyst Count | 13 |
Scores
Altman Z-Score | 4.05 |
Piotroski F-Score | 4 |